Gene Therapy Composition for Pain Relief via Synergistic GAD and IL-10 Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain relief medications, such as NSAIDs and sodium channel blockers, often require high doses and can cause significant side effects like gastric damage and toxicity, limiting their effectiveness for chronic pain.
Innovation Solution
A pharmaceutical composition comprising a gene encoding glutamate decarboxylase (GAD) and an anti-inflammatory cytokine, such as IL-10, administered via viral vectors like adeno-associated viruses, to provide analgesic relief with reduced side effects and toxicity at lower doses through synergistic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of NSAIDs are administered to achieve effective pain relief, then analgesic efficacy is improved, but gastric damage and gastrointestinal bleeding occur
Solution Approach 1:
The patent changes the fundamental parameter of analgesic delivery from chemical compounds (NSAIDs) to genetic material (genes encoding GAD and anti-inflammatory cytokines). This parameter change allows the body to produce the therapeutic proteins endogenously at controlled levels, achieving effective pain relief without the dose-dependent gastric toxicity associated with high-dose NSAID administration
Solution Approach 2:
The patent introduces viral vectors as intermediaries to deliver genetic material into target cells. These vectors act as mediators that enable controlled expression of GAD and anti-inflammatory cytokine genes, producing analgesic effects through endogenous protein synthesis rather than direct administration of toxic chemical analgesics
2Reliability
If high doses of acetaminophen are administered to achieve effective pain relief, then analgesic efficacy is improved, but liver damage occurs
Solution Approach 1:
The patent transitions from administering exogenous chemical analgesics that require metabolic processing (and thus liver exposure) to delivering genetic material that enables endogenous production of therapeutic proteins. This parameter change eliminates the need for hepatic metabolism, preventing liver damage while maintaining analgesic efficacy
Solution Approach 2:
The patent replaces the chemical-metabolic mechanism of traditional analgesics with a genetic-expression mechanism. Instead of administering chemicals that must be metabolized by the liver, the system uses viral vectors to deliver genes that are expressed directly in target tissues, substituting the metabolic pathway with a transcriptional-translation pathway that bypasses liver toxicity
3Duration of action of stationary object
If long-term use of analgesics is continued to maintain pain relief, then duration of action is improved, but resistance and loss of efficacy occur
Solution Approach 1:
The patent enables the body's own cells to produce therapeutic proteins through delivered genetic material. The endogenous production of GAD and anti-inflammatory cytokines by target cells creates a self-sustaining therapeutic effect that does not induce resistance, as the body is producing the proteins itself rather than responding to external chemical agents
Solution Approach 2:
The patent uses low doses of viral vectors delivering genetic material, which is then amplified endogenously within target cells. This partial action approach (small initial genetic dose) results in excessive production of therapeutic proteins by the infected cells, achieving long-lasting analgesic effects without the resistance problems associated with continuous chemical analgesic administration
4Reliability
If sodium channel blockers are administered to achieve pain relief, then analgesic efficacy is improved, but cardio-toxicity and motor impairment occur
Solution Approach 1:
The patent achieves localized production of therapeutic proteins at the site of pain or inflammation through targeted gene delivery. The viral vectors infect specific cells in the affected area, causing local expression of GAD and anti-inflammatory cytokines, thereby providing analgesic effects without systemic distribution that would cause cardio-toxicity
Solution Approach 2:
The patent uses viral vectors as intermediaries to deliver genetic material specifically to target cells in the affected tissue. This intermediary approach enables localized therapeutic protein production, avoiding the systemic circulation and cardiac exposure that cause toxicity with conventional sodium channel blocker administration
Data Source
AI summary
A composition useful for alleviating or treating pain and uses thereof are disclosed. The composition containing glutamate decarboxylase and a gene coding for an anti-inflammatory cytokine. A method for alleviating or treating pain of a subject includes administering the composition to the subject.